DENVER--(BUSINESS WIRE)--June 14, 2006--Ceragenix Pharmaceuticals, Inc. today announced that the FDA's Office of Combination Products (www.fda.gov/oc/combination) in response to the Company's formal request has determined that Cerashield's(TM) primary mode of action is that of a device and it has been assigned to the FDA's Center for Devices and Radiologic Health (CDRH) for lead review. The device will be reviewed through the pre-market approval process to confirm reasonable assurance of safety and effectiveness.
